Verkazia 1 mg/mL eye drops clinical trials

Efficacy and safety assessment of T1695 ophthalmic suspension, versus Ciclosporin ophthalmic emulsion, in participants with moderate to severe Vernal Keratoconjunctivitis (VKC)

This study is testing a new eye drop (T1695) for a severe form of eye allergy called Vernal Keratoconjunctivitis (VKC). It compares T1695 to an existing treatment (Ciclosporin eye drops) to see how well it helps improve eye damage and symptoms in people aged 12-14.